MedTrace Logo

ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)

NCT03026205 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-04-17

No results posted yet for this study

Summary

This is a single center study to evaluate the pharmacokinetics of ARMS-I a formulation that incorporates cetylpyridinium chloride (CPC), administered once as a single dose of three sprays orally, followed by multiple dosing (3x daily oral sprays) over days 3-6 and then a repeat pharmacokinetic study during the final oral dose administered as the first dose on day 7 to ascertain CPC accumulation.

Conditions

  • Viral Upper Respiratory Tract Infection

Interventions

DRUG

ARMS-I

Sponsors & Collaborators

  • ProMedica Health System

    collaborator OTHER

  • The University of Toledo

    collaborator UNKNOWN

  • ARMS Pharmaceutical LLC

    collaborator UNKNOWN

  • Pediatric Pharmacology Research Center

    collaborator UNKNOWN

  • University of Toledo Health Science Campus

    lead OTHER

Principal Investigators

  • Jeffrey L Blumer, PhD, MD · Professor, University of Toledo

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03026205 on ClinicalTrials.gov